MicroRNA profiles classify papillary renal cell carcinoma subtypes
暂无分享,去创建一个
A. Ekici | A. Hartmann | H. Taubert | S. Wach | B. Wullich | T. Rau | B. Keck | H Taubert | S Wach | E Nolte | A Theil | C Stöhr | T T Rau | A Hartmann | A Ekici | B Keck | B Wullich | C. Stöhr | A. Theil | A. Hartmann | E. Nolte | T. T. Rau
[1] Zhe-Sheng Chen,et al. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases , 2011, The FEBS journal.
[2] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[3] George M Yousef,et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. , 2011, European urology.
[4] Heng Tao Shen,et al. Principal Component Analysis , 2009, Encyclopedia of Biometrics.
[5] P. Lara,et al. Renal cell carcinoma: current status and emerging therapies. , 2007, Cancer treatment reviews.
[6] J. Steitz,et al. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR , 2007, Proceedings of the National Academy of Sciences.
[7] Jörg Grigull,et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. , 2011, The Journal of urology.
[8] C. Bracken,et al. The role of microRNAs in metastasis and epithelial-mesenchymal transition , 2009, Cellular and Molecular Life Sciences.
[9] A. Disch,et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. , 2011, Analytical biochemistry.
[10] P. Choyke,et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.
[11] Christina Backes,et al. Toward the blood-borne miRNome of human diseases , 2011, Nature Methods.
[12] Bin Tean Teh,et al. MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.
[13] A. Evans,et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215 , 2011, British Journal of Cancer.
[14] Xin Huang,et al. MiR-210--micromanager of the hypoxia pathway. , 2010, Trends in molecular medicine.
[15] I. Sesterhenn,et al. World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .
[16] Arif B Ekici,et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening , 2012, International journal of cancer.
[17] Michael A. S. Jewett,et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. , 2012, Journal of Molecular Diagnostics.
[18] Hailong Wu,et al. p53 represses c-Myc through induction of the tumor suppressor miR-145 , 2009, Proceedings of the National Academy of Sciences.
[19] Ricky T. Tong,et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. , 2009, Molecular cell.
[20] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[21] Bin Tean Teh,et al. A molecular classification of papillary renal cell carcinoma. , 2005, Cancer research.
[22] B. Delahunt,et al. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[23] H. Kung,et al. MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.
[24] Wei Guo,et al. Identification of miRs-143 and -145 that Is Associated with Bone Metastasis of Prostate Cancer and Involved in the Regulation of EMT , 2011, PloS one.
[25] C. Elie,et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. , 2007, Urology.
[26] Gunter Meister,et al. miRNAs Get an Early Start on Translational Silencing , 2007, Cell.
[27] W. Linehan,et al. Intrinsic drug resistance in primary and metastatic renal cell carcinoma. , 1999, The Journal of urology.
[28] G. Kristiansen,et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.
[29] L. Thomas,et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma , 2011, Journal of Medical Genetics.
[30] Ximing J. Yang,et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. , 2007, Cancer research.
[31] G. Bhanot,et al. Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.
[32] Jelle J. Goeman,et al. Genome-Wide MicroRNA Expression Analysis of Clear Cell Renal Cell Carcinoma by Next Generation Deep Sequencing , 2012, PloS one.
[33] Christina Backes,et al. GeneTrail—advanced gene set enrichment analysis , 2007, Nucleic Acids Res..
[34] L. O’Driscoll,et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma , 2009, BMC urology.
[35] A. Poprach,et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients , 2012, Genes, chromosomes & cancer.
[36] M. F. Shannon,et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.
[37] Hans Lehrach,et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy , 2009, Journal of cellular and molecular medicine.
[38] Han Yong Choi,et al. The epidemiology of renal cell carcinoma. , 2011, European urology.